Sie suchten nach: physical therapy for degenerative elbow (Spanisch - Englisch)

other organ physical therapy
other organ physical therapy

ingelheim-initiation therapy for -5 mg/ml
-solution for injection -5 mg/ml

points to consider on xenogeneic cell therapy for medicinal products
points to consider on xenogeneic cell therapy for medicinal products

b01ax anti-coagulation therapy for heparin- associated throm bocytopenia
b01ax anti-co agulation therapy for heparin- associated thrombocytopenia

community-based therapy for multidrug-resistant tuberculosis in lima, peru.
community-based therapy for multidrug-resistant tuberculosis in lima, peru.

initiation therapy for - 5 mg/ml alleviation of pain and - 1 inflammation (qm01ac06)
r06ax27 relief of symptoms associated with seasonal allergic rhinitis

-meloxicam ingelheim -initiation therapy for -5 mg/ml -10.11.1999 -
-05.12.2000 --a-neurobloc -botulinum

otro estudio publicado en "physial therapy" de la american physical therapy association se centró en el uso de wii para la rehabilitación de un adolescente que padecía de parálisis cerebral.
a case study published in the american physical therapy association's journal, "physical therapy", focused on use of the wii for rehabilitation in a teenager with cerebral palsy.

a) b01ax b) anti-coagulation therapy for heparin-associa-ted thrombo-cytopenia
a) b01ax b) anti-coagulation therapy for

* "feeling better, getting better, staying better: profound self-help therapy for your emotions".
* "feeling better, getting better, staying better: profound self-help therapy for your emotions".

dice la american physical therapy association (asociación estadounidense de fisioterapia): “un límite arbitrario para los servicios ambulatorios de terapia que no tenga en cuenta la idoneidad clínica de la atención discrimina contra los beneficiarios de medicare más vulnerables”.
says the american physical therapy association: "an arbitrary cap on outpatient therapy services without regard to clinical appropriateness of care discriminates against the most vulnerable medicare beneficiaries."

el pinamonti physical therapy & wellness center de pittsburg, kansas, cuenta con sistemas, opciones y servicios combinados de manera holística para garantizar un programa completo que mejore el estilo de vida de sus miembros y pacientes. desde el principio, el equipo de fitness con el que ha trabajado ha sido technogym.
pinamonti physical therapy & wellness center in pittsburg, kansas has systems, features and services, holistically combined to assure an overall programme that improves its members’ and patients’ lifestyles.from the beginning, the fitness equipment that has been used has been technogym.

points to consider on the requirements for clinical documentation for metered dose inhalers (mdi)" farmacovigilancia " título del documento concept paper on conduct of pharmacovigilance for medicines used by children points to consider on xenogeneic cell therapy for medicinal products addendum to ich e2c ­ clinical safety data management:periodic safety update reports for marketed drugs" seguridad " título del documento points to consider on the need for assessment of reproductive toxicity of human insulin analogues concept paper on the development of a cpmp position paper on the non-clinical safety studies to support low dose clinical screening studies in humans position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound note for guidance on photosafety testing note for guidance on specification limits for residues of metal catalysts swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment note for guidance on carcinogenic potential
cpmp/swp/5199/02points to consider on the need for assessment of reproductive toxicity of human insulin analogues concept paper on the development of a cpmp position paper on the non-clinical safety studies to support low dose clinical screening studies in humans note for guidance on photosafety testing swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment note for guidance on carcinogenic potential position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound note for guidance on specification limits for residues of metal catalysts note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance: